{"id":"NCT01087788","sponsor":"UCB BIOSCIENCES GmbH","briefTitle":"Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis","officialTitle":"Phase 3, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Adult-Onset Active and Progressive Psoriatic Arthritis (PsA)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-03","primaryCompletion":"2011-11","completion":"2015-08","firstPosted":"2010-03-16","resultsPosted":"2014-02-25","lastUpdate":"2018-08-01"},"enrollment":409,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Arthritis, Psoriatic"],"interventions":[{"type":"BIOLOGICAL","name":"CZP 200 mg Q2W","otherNames":["Cimzia","Certolizumab Pegol"]},{"type":"BIOLOGICAL","name":"CZP 400 mg Q4W","otherNames":["Cimzia","Certolizumab Pegol"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"CZP 200 mg Q2W","type":"EXPERIMENTAL"},{"label":"CZP 400 mg Q4W","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Placebo to CZP 200 mg escape on Week 16","type":"OTHER"},{"label":"Placebo to CZP 400 mg escape on Week 16","type":"OTHER"},{"label":"Placebo to CZP 200 mg on Week 24","type":"OTHER"},{"label":"Placebo to CZP 400 mg on Week 24","type":"OTHER"}],"summary":"Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of Certolizumab Pegol (CZP) in subjects with adult onset active and progressive Psoriatic Arthritis (PsA).","primaryOutcome":{"measure":"American College of Rheumatology 20 (ACR20) Response at Week 12","timeFrame":"Week 12","effectByArm":[{"arm":"Placebo (Randomized Set)","deltaMin":24.3,"sd":null},{"arm":"CZP 200 mg Q2W (Randomized Set)","deltaMin":58,"sd":null},{"arm":"CZP 400 mg Q4W (Randomized Set)","deltaMin":51.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":10},"locations":{"siteCount":92,"countries":["United States","Argentina","Belgium","Brazil","Canada","Czechia","France","Germany","Hungary","Ireland","Italy","Mexico","Poland","Spain","United Kingdom"]},"refs":{"pmids":["23942868","23942869","29556416","30191421","27696727","24996416","24942382","24339179"],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":49,"n":198},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Pharyngitis","Bronchitis","Back pain"]}}